Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
-
Published:2025-06
Issue:
Volume:
Page:
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Mayadev J., Vázquez Limón J.C., Ramírez Godinez F.J., Leiva M., Cetina-Pérez L.D.C.ORCID, Varga S., Molina Alavez A., Alarcon-Rozas A.E.ORCID, Valdiviezo N., Acevedo C., Figueroa A., Santini A., Vera L.ORCID, Rey F., Kahán Z., Galaz P., Meléndez Mier G., Wu X., Mandai M.ORCID, Shapira-Frommer R., Estevez-Diz M.D.P.ORCID, Limaye S., Xin W., Dry H., Broggi M.A.S.ORCID, Yuan D.Y., Stewart R.A., Monk B.J.ORCID
Reference19 articles.
1. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial;Monk;Lancet Oncol,2023 2. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial;Lorusso;Lancet,2024 3. Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer;Han;J Clin Oncol,2024 4. Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer;Jeannot;Clin Cancer Res,2021 5. Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker;Li;Cancer Cell Int,2023
|
|